Chart, page-2340

For me the August price drop was a classic shakeout on higher volumes. Since then volumes have been moderate with a steady decline into anticipation of a good outcome from the FDA followed by disappointment and consolidation around converging support and resistance lines based on long term sentiment, for now.
Bell Potter wrote in part, today:
Once the FDA opens the IND, PAR should commence recruitment relatively quickly with first patients dosed early in the new year in the US. First patient in Australia may be dosed this year. The commencement of recruitment was due to have started in the September quarter of CY2021, hence these delays with the IND have pushed the timetable back by approximately six months.
Upcoming catalyst include the opening of the IND and an update on the synovial fluid biomarker study (PAR008) being recruited in Australia.

Hard to see @twincreeks upswing, looks to me like staying between the red and blue, with any upside dependent on announcements.
Maybe then it will break the higher redline.
GLTAH.
IMO. DYOR.